Plasmacytoma-like post-transplant lymphoproliferative disorder seen in pediatric combined liver and intestinal transplant recipients

2013 ◽  
Vol 60 (11) ◽  
pp. E137-E139 ◽  
Author(s):  
Ashley S. Plant ◽  
Robert S. Venick ◽  
Douglas G. Farmer ◽  
Shivani Upadhyay ◽  
Jonathan Said ◽  
...  
Keyword(s):  
Lymphoproliferative Disorder ◽  
Transplant Recipients ◽  
Post Transplant ◽  
Intestinal Transplant

Post-transplant lymphoproliferative disorder in pediatric intestinal transplant recipients: A literature review

2018 ◽  
Vol 22 (5) ◽  
pp. e13211 ◽  
Author(s):  
Kaitlin Stanley ◽  
Erika Friehling ◽  
Sarangarajan Ranganathan ◽  
George Mazariegos ◽  
Linda M. McAllister-Lucas ◽  
...  
Keyword(s):  
Literature Review ◽  
Lymphoproliferative Disorder ◽  
Transplant Recipients ◽  
Post Transplant ◽  
Intestinal Transplant

A systematic review of post-transplant lymphoproliferative disorder after lung transplant.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e19046-e19046
Author(s):  
Mobeen Zaka Haider ◽  
Zarlakhta Zamani ◽  
Fnu Kiran ◽  
Hasan Mehmood Mirza ◽  
Muhammad Taqi ◽  
...  
Keyword(s):  
Lymphoproliferative Disorder ◽  
Lung Transplant ◽  
Late Onset ◽  
Adult Population ◽  
Solid Organ Transplantation ◽  
Chemotherapeutic Agents ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Post Transplant ◽  
Lung Transplant Recipients

e19046 Background: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after solid organ transplantation. This study aims to explore the association of PTLD diagnosed after lung transplant with infectious agents and immunosuppression regimen, explore types of PTLD, and their outcome. Methods: Following the PRISMA guideline, we searched the literature on PubMed, Cochrane, Embase, and clinicaltrials.gov. 1741 articles were screened and included five studies. Results: We analyzed data from five studies, n=13,643 transplant recipients with n=287 (2.10%) developed PTLD. Four studies showed that 32/63 (51%) PTLD patients were male and 31 (49%) were female. Three studies reported 53/55 (96.4%) patients were EBV positive at PTLD diagnosis. Courtwright. et al, reported that 217/224 (97%) PTLD was associated with either EBV positive donor or recipient. Four studies showed that the monomorphic B cell type 48/63 (76%) was the most common histological type of PTLD diagnosed with DLBCL the most common subtype 31/48 (64.6%). Data from 3 studies showed that the onset of PTLD following lung transplant varies with a median duration of 18.3 months (45 days to 20.2 years). Three studies showed that 26/55 (47.3%) patients had early-onset (≤ 1 yr of Tx) and 29/55 (52.7%) patients had late-onset PTLD (> 1 yr of Tx). Management of PTLD included a reduction in immunosuppression including corticosteroids, CNI, purine synthesis inhibitors, Rituximab, and chemotherapeutic agents. Three studies showed a mortality rate of 30/45 (66.7%) and 13/30 (43.3%) deaths were PTLD related. Conclusions: Our review concludes that PTLD is a serious complication, only 2% of lung transplant recipients developed PTLD. EBV seropositivity is the most factor associated with PTLD diagnosis. Monomorphic PTLD was reported as the most common type in the adult population and no association between gender and PTLD was found. The analysis shows that there is a slightly lower incidence of early (≤ 1 yr of Tx) than late-onset (> 1 yr of Tx) PTLD. Table 1 PTLD after a Lung transplant in adults - a review. [Table: see text]

scholarly journals Hypomagnesemia and risk of post‐transplant lymphoproliferative disorder in liver transplant recipients

2020 ◽  
Vol 33 (12) ◽  
pp. 1835-1836
Author(s):  
Parag Mahale ◽  
Gregory J. Mckenna ◽  
Giovanna Saracino ◽  
Linda Jennings ◽  
Sam M. Mbulaiteye ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Lymphoproliferative Disorder ◽  
Transplant Recipients ◽  
Post Transplant ◽  
Liver Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document